Intriguingly, higher MARCHF9 expression predicted worse survival in COAD patients with high MSI, suggesting that MARCHF9 may have a detrimental impact on prognosis in this specific molecular subgroup (Figure 3(c), P=0.016). Here, MARCHF9 is linked to colon adenocarcinoma.